An Improved 211At-Labeled Agent for PSMA-Targeted α-Therapy

Ronnie C. Mease; Choong Mo Kang; Vivek Kumar; Sangeeta Ray Banerjee; Il Minn; Mary Brummet; Kathleen L. Gabrielson; Yutian Feng; Andrew Park; Ana P. Kiess; George Sgouros; Ganesan Vaidyanathan; Michael R. Zalutsky; Martin G. Pomper

doi:10.2967/jnumed.121.262098

Research ArticleFeatured Basic Science Article

An Improved ²¹¹At-Labeled Agent for PSMA-Targeted α-Therapy

Ronnie C. Mease, Choong Mo Kang, Vivek Kumar, Sangeeta Ray Banerjee, Il Minn, Mary Brummet, Kathleen L. Gabrielson, Yutian Feng, Andrew Park, Ana P. Kiess, George Sgouros, Ganesan Vaidyanathan, Michael R. Zalutsky and Martin G. Pomper

Journal of Nuclear Medicine February 2022, 63 (2) 259-267; DOI: https://doi.org/10.2967/jnumed.121.262098

Ronnie C. Mease

1Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Choong Mo Kang

2Department of Radiology, Duke University Medical Center, Durham, North Carolina;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Vivek Kumar

1Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Sangeeta Ray Banerjee

1Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Il Minn

1Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Mary Brummet

1Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Kathleen L. Gabrielson

3Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, Maryland; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Yutian Feng

2Department of Radiology, Duke University Medical Center, Durham, North Carolina;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Andrew Park

1Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ana P. Kiess

4Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

George Sgouros

1Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland;

4Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ganesan Vaidyanathan

2Department of Radiology, Duke University Medical Center, Durham, North Carolina;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Michael R. Zalutsky

2Department of Radiology, Duke University Medical Center, Durham, North Carolina;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Martin G. Pomper

1Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland;

4Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

Data supplements

Supplemental Data

Files in this Data Supplement:

Supplemental Data

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 63, Issue 2

February 1, 2022

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Complete Issue (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following An Improved 211At-Labeled Agent for PSMA-Targeted α-Therapy

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

An Improved ²¹¹At-Labeled Agent for PSMA-Targeted α-Therapy

Journal of Nuclear Medicine Feb 2022, 63 (2) 259-267; DOI: 10.2967/jnumed.121.262098

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

An Improved ²¹¹At-Labeled Agent for PSMA-Targeted α-Therapy

Journal of Nuclear Medicine Feb 2022, 63 (2) 259-267; DOI: 10.2967/jnumed.121.262098

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

PubMed
Google Scholar

Cited By...

Is 211At Really Happening?
Development and Preclinical Evaluation of [211At]PSAt-3-Ga: An Inhibitor for Targeted {alpha}-Therapy of Prostate Cancer
Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose 211At-Labeled Anti-HER2 Single-Domain Antibody Fragment

Google Scholar

Keywords

prostate cancer
α-emitter
radiopharmaceutical therapy
211At
PSMA
murine models

Main menu

User menu

Search

An Improved ²¹¹At-Labeled Agent for PSMA-Targeted α-Therapy

Data supplements

Supplemental Data

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords